FAUSTINI, GAIA
 Distribuzione geografica
Continente #
NA - Nord America 1.508
EU - Europa 1.336
AS - Asia 403
SA - Sud America 6
OC - Oceania 4
AF - Africa 2
Totale 3.259
Nazione #
US - Stati Uniti d'America 1.499
PL - Polonia 659
CN - Cina 216
IT - Italia 210
UA - Ucraina 158
DE - Germania 94
HK - Hong Kong 67
FI - Finlandia 59
SG - Singapore 42
FR - Francia 41
IE - Irlanda 39
GB - Regno Unito 38
VN - Vietnam 36
IN - India 21
SE - Svezia 13
CZ - Repubblica Ceca 11
CA - Canada 9
BE - Belgio 8
TR - Turchia 5
KR - Corea 4
AU - Australia 3
BR - Brasile 3
IL - Israele 3
IR - Iran 3
EG - Egitto 2
GR - Grecia 2
JO - Giordania 2
JP - Giappone 2
AR - Argentina 1
BD - Bangladesh 1
BO - Bolivia 1
CL - Cile 1
EE - Estonia 1
LA - Repubblica Popolare Democratica del Laos 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RU - Federazione Russa 1
Totale 3.259
Città #
Warsaw 659
Fairfield 201
Jacksonville 128
Chandler 120
Ashburn 110
Woodbridge 101
Brescia 86
Cambridge 86
Seattle 83
Dearborn 77
Houston 72
Princeton 72
Wilmington 68
Hong Kong 66
Ann Arbor 61
Beijing 52
Helsinki 50
New York 45
Dublin 39
Dong Ket 36
Nanjing 33
Singapore 28
Milan 22
Boardman 18
Jinan 16
Shanghai 16
Des Moines 13
Pune 13
San Diego 13
San Giuliano Milanese 13
Shenyang 13
Hebei 11
Brno 10
Changsha 8
Brussels 7
Cattolica 7
Lappeenranta 7
Rome 7
San Donà Di Piave 7
Tianjin 7
Toronto 7
Lanzhou 6
Nanchang 6
Pavia 6
San Francisco 6
Taizhou 6
Hangzhou 5
Jiaxing 5
Kunming 5
Oxford 5
San Cesareo 5
Hefei 4
London 4
Los Angeles 4
Napoli 4
Ningbo 4
Providence 4
Zhengzhou 4
Ardabil 3
Augusta 3
Fulda 3
Guangzhou 3
Haikou 3
Kafr Manda 3
Kilburn 3
Leawood 3
Norwalk 3
Paris 3
Taiyuan 3
Ulsan 3
Amman 2
Cairo 2
Canberra 2
Mineola 2
Munich 2
Padova 2
São Paulo 2
Tokyo 2
Trento 2
Verona 2
West Jordan 2
Amstelveen 1
Atlanta 1
Auckland 1
Baotou 1
Blackpool 1
Bocholt 1
Bristol 1
Buenos Aires 1
Camerino 1
Castelfranci 1
Central 1
Chicago 1
Coccaglio 1
Dhaka 1
Falkenstein 1
Fremont 1
Gunzenhausen 1
Hounslow 1
Imperia 1
Totale 2.648
Nome #
Dopamine transporter/α-synuclein complexes are altered in the post mortem caudate putamen of Parkinson’s disease: An in situ proximity ligation assay study 247
Anionic liposomes for siRNA delivery to primary neuronal cells: evaluation of Alpha synuclein knockdown efficacy 239
The Contribution of -Synuclein Spreading to Parkinson’s Disease Synaptopathy 220
Living in promiscuity: The multiple partners of alpha-synuclein at the synapse in physiology and pathology 177
Mitochondria and alpha-synuclein: Friends or foes in the pathogenesis of Parkinson's disease? 170
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains 153
Alpha-Synuclein Preserves Mitochondrial Fusion and Function in Neuronal Cells 141
NF-κB/c-Rel deficiency causes Parkinson's disease-like prodromal symptoms and progressive pathology in mice 134
Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy 121
Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate 112
Synapsin III alterations in Parkinson's disease 108
Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons 105
Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson’s Disease 92
Involvement of Synapsin III in the onset of alpha-synuclein synaptic pathology in Parkinson’s disease 88
Parkinson's disease: from synaptic loss to connectome dysfunction 76
Study of alpha-synuclein fibrillation: State of the art and expectations 76
Involvement of Synapsin III in the onset of Alpha-synuclein pathology in Parkinson’s Disease 75
Synapsin III knock-out reduces AAV-alpha-synuclein overexpression-related neuropathology in the nigrostriatal system 69
AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons of Synapsin III knockout mice reveals novel molecular features involved in Parkinson's disease pathology. 68
The good and bad of therapeutic strategies that directly target α-synuclein 66
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of Parkinson’s disease and dementia with Lewy bodies, 65
Synapsin III and Alpha-Synuclein cooperation in the onset of synaptic pathology in Parkinson’s Disease 65
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson’s disease 65
Design and Synthesis of Fluorescent Methylphenidate Analogues for a FRET-Based Assay of Synapsin III Binding 63
Exploring LRRK2-dependent clearance of α-synuclein pffs in glial cells via clusterin 62
Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives 56
. Alpha-synuclein is a crucial mediator of mitochondrial fusion and functions 55
Alpha-synuclein absence affected mitochondrial fusion and functions 47
Extracellular clusterin limits the uptake of α-synuclein fibrils by murine and human astrocytes 47
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and synaptic protein’s redistribution 44
Alpha-Synuclein is Involved in DYT1 Dystonia Striatal Synaptic Dysfunction 36
An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders 32
The association between α-synuclein and α-tubulin in brain synapses 29
Validation of synapsin III as a therapeutic target for Parkinson’s disease in the AAV-mediated alpha-synuclein mouse model 28
Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype 27
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease 26
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy? 18
Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice 16
Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson's Disease 12
Synapsin III Regulates Dopaminergic Neuron Development in Vertebrates 10
DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease 10
Totale 3.350
Categoria #
all - tutte 14.786
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.786


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020948 80 42 39 56 61 133 105 115 78 127 64 48
2020/2021716 39 59 36 74 58 59 26 76 68 92 65 64
2021/2022339 29 43 23 12 4 28 13 28 19 25 41 74
2022/2023376 50 1 10 30 35 93 3 38 64 10 18 24
2023/2024422 35 8 39 37 20 80 17 16 73 10 14 73
2024/20251 1 0 0 0 0 0 0 0 0 0 0 0
Totale 3.350